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Specific antisera were generated to characterize Epstein-Barr virus proteins reported to have trans-activating
properties. Open reading frame BRLF1 was found to be expressed in two modifications in vivo, with molecular
sizes ranging from 94 to 98 kilodaltons (kDa) depending on the cell line, whereas only one protein (Raji cells,
96 kDa) was detected by in vitro translation. Open reading frame BZLF1 encoded polypeptides of 38 and 35
kDa and additional smaller forms. A BZLF1-encoded 30-kDa protein could be detected under conditions in
which expression was restricted to immediate early genes. Nuclear localization could be shown for the proteins
derived from reading frames BZLF1 and BMLF1. BMLF1 expression gave a heterogeneous protein pattern,
with molecular sizes between 45 and 70 kDa, including a predominant 60-kDa protein detected in different
B-cell lines.
To understand the regulatory events of primary infection,
maintenance of latency, or tumor development, it is essential
to study the initial steps in Epstein-Barr virus (EBV) gene
activation (2, 4, 35). In latently infected cells, viral gene
expression is restricted to a few viral products: EBV nuclear
antigens (3, 11, 16, 22, 34, 40), BNLF1 membrane protein
("latent" membrane protein) (26), EBV-encoded small
RNAs (18), and terminal protein (23). The expression of
these genes is dependent on the host cell (33), suggesting a
close interaction of viral and cellular factors. Regulatory
aspects of the lytic cycle of EBV based on localization of
viral genes on the genome (7, 19, 37) and definition of
immediate early (4, 35; K. Fuchs, M.S. thesis, Max von
Pettenkofer-Institute, University of Munich, Munich, Fed-
eral Republic of Germany, 1986) or latency disrupting (8, 9)
genes are now studied in detail by functional analysis (5, 24).
Transfection experiments revealed trans-acting properties
for the poorly characterized gene products of the EBV open
reading frames (ORFs) BZLF1 (5, 8, 9, 14, 39), BMLF1 (5,
21, 24, 27, 41), and BRLF1 (15). Expression of BZLF1 is
sufficient to disrupt latency in B cells (5, 8). trans-Activation
by the spliced BMLF1-BSLF2 product is nonspecific with
respect to the target gene and host cell system, as shown by
cotransfection assays using different promoters of herpes
simplex virus or unrelated viruses (adenovirus, simian virus
40, and human immunodeficiency virus) (21, 24, 41). The
BRLF1-encoded trans-activator is capable of inducing the
expression of the early BHRF1 ORF (15).
These results indicate the important regulatory functions
of BZLF1, BMLF1, and BRLF1, but little information has
been given about the polypeptides mapping in these genes.
Previously published results from our group described the in
vitro translation pattern of hybrid-selected RNA specific for
BZLF1 and BRLF1 (36, 37). In the present work we char-
acterize in vivo proteins encoded by these ORFs and show
their cellular localizations and molecular weights and the
presence of modified forms in lymphoid cell lines.
Subfragments of the three ORFs were cloned in pUR
vectors and expressed as fusion proteins with 3-galactosi-
dase. The ORF BMLF1 was subcloned from the BamHI M
fragment of EBV B95-8 DNA (38). A BamHI-XhoI fragment
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of 609 base pairs encoding 165 N-terminal amino acids was
cloned in frame with 3-galactosidase into pUR289 and di-
gested with BamHI-SalI. The coding sequences for the
expression of BRLF1 and BZLF1 were derived from the
SalI C fragment of EBV M-ABA DNA (31) and subcloned in
pUC vectors as described previously (36). The HindIII-XbaI
fragment encoding 400 C-terminal amino acids of BRLF1
was ligated with pUR288. For the expression of 110 C-
terminal amino acids of BZLF1, a HindlII-XbaI fragment
had to be subcloned in pINIII Bi to gain BamHI-XbaI sites
for insertion in pUR289.
Detection of the EBV-specific epitopes in Western blots
(immunoblots) by a pool of human sera (patients with
nasopharyngeal carcinoma) showed the presence of viral
antigenic sites. The specificity of human antibodies to the
EBV portion of the fusion proteins was ensured by using
sera with low 3-galactosidase reactivity. The fusion protein
preparations were partially purified by the isolation of insol-
uble inclusion bodies (25) and were used to generate reading
frame-specific rabbit antisera.
The localization of viral antigens was shown by immuno-
fluorescence tests with acetone-fixed, chemically induced
Raji, P3HR-1, and B95-8 cells (40 nM phorbol-12-mystrate-
13-acetate [TPA]-3 mM butyrate; induction for 2 days) or
superinfected Raji and freshly infected BJA-B cells (8 hours
postinfection; virus prepared from P3HR-1 cells). In these
cells specific signals could be obtained with each of the three
antisera (rabbit sera were diluted 1:50 in BJA-B cell extracts
for preadsorption; fluorescein-isothiocyanate-conjugated an-
ti-rabbit antibodies from Dakopatts were used in a dilution of
1:100), whereas untreated latent Raji cells or EBV-negative
BJA-B cells gave no positive reaction (Fig. 1A). When
BRLF1-specific serum was used, antigens were detected in
the cytoplasm and nuclei of induced P3HR-1 cells (Fig. 1B).
In B95-8 cell preparations, BZLF1- as well as BMLF1-
specific proteins could be demonstrated to be restricted to
nuclear compartments (Fig. 1C and F). These results confirm
earlier reports on the expression of nuclear antigens from the
ORFs BMLF1 and BZLF1 (6, 9, 14, 41). In infected BJA-B
cells (P3HR-1 virus), BMLF1- or BZLF1-specific fluores-
cence was detected in the nuclei and cytoplasm starting at
between 6 and 12 h postinfection (Fig. 1D).
For further analysis of the proteins, we used Western
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FIG. 1. Indirect immunofluorescence of acetone-fixed cells with
ORF-specific rabbit sera and fluorescein-isothiocyanate-conjugated
anti-rabbit antibodies. The cells were either infected with P3HR-1
virus (D) or induced with TPA-butyrate (A through C, E, and F). (A)
Preimmune serum, Raji cells; (B) BRLF1-specific serum, P3HR-1
cells; (C) BZLF1-specific serum, B95-8 cells; (D) BZLF1-specific
serum, infected BJA-B cells; (E) BZLF1-specific serum, P3HR-1
cells; (F) BMLF1-specific serum B95-8 cells.
blotting techniques (methods modified from those described
in reference 36). Samples (106 cells) were sonicated and
separated on 10 to 15% sodium dodecyl sulfate-polyacryl-
amide gels. Western blots from gels with different cell
extracts were incubated at room temperature overnight in a
1:50 dilution of rabbit antisera, and color reactions were
achieved after incubation for 2 h with either peroxidase
(POD)- or alkaline phosphatase (AP)-conjugated anti-rabbit
antibodies (dilution, 1:1,000) with different substrates.
Brown POD substrate was 0.5 mg of 3,3'-diaminobenzidine
per ml, 0.01% hydrogen peroxide, and 50 mM Tris (pH 7.5).
Red AP substrate was 1 mg of Fast Red (Bio-Rad Labora-
tories) per ml, 0.5 mg of 4-chloro-1-naphthol per ml, 50 mM
Tris (pH 9.5), and 0.5 mM MgCl2. Violet AP substrate was
0.3 mg of Nitro Blue Tetrazolium (Sigma Chemical Co.) and
0.15 mg of 5-bromo-4-chloro-3-indolyl phosphate (Sigma)
per ml, both dissolved in dimethylformamide and diluted
1: 100 in carbonate buffer (0.1 M NaHCO3, 1 mM MgCl2; pH
9.8).
Western blot analysis of BZLF1, BRLF1, and BMLF1
expression comparing EBV-positive (B95-8, P3HR-1, and
FIG. 2. Western blot analysis of different cell extracts after serial
serum incubation and staining procedures as described in the text
(POD and AP conjugates with specific color substrates). The mo-
lecular sizes of specific proteins are discussed in the text and
summarized in Fig. 4. (A) BMLF1-specific serum (AP, violet).
Lanes: 1, BJA-B; 2, P3HR-1 induced with TPA-butyrate; 3, B95-8;
4, Raji; 5, Raji induced with TPA-butyrate. (B) Incubation 1,
BZLF1-specific serum (AP, violet); Incubation 2, BMLF1-specific
serum (AP, red). Lanes: 1, Raji; 2, Raji induced with TPA-butyrate;
3, BJA-B; 4, P3HR-1 induced with TPA-butyrate. (C) Incubation 1,
BRLF1-specific serum (AP, violet); incubation 2, EBNA1-specific
serum (POD, brown). Lanes: 1, Raji; 2, Raji induced with TPA-
butyrate; 3, BJA-B; 4, P3HR-1 induced with TPA-butyrate. (D)
Incubation 1, BZLF1-specific serum (AP, red); incubation 2,
BRLF1-specific serum (POD, brown); incubation 3, BMLF1-spe-
cific serum (AP, violet). Lanes: 1, Raji; 2, Raji induced with TPA-
butyrate; 3, Raji.
Raji) and EBV-negative (BJA-B) B-cell lines showed that
each ORF encoded proteins in at least two different modifi-
cations. Untreated Raji or B95-8 cells representing the latent
state of infection did not express measurable amounts of
trans-activator proteins. Chemical induction with TPA and
butyrate led to the expression of specific polypeptides which
varied in quantity relative to each other, as shown by serial
incubation of ORF-specific sera on Western blots (Fig. 2).
The virus strain-specific molecular size of EBNA1 (68 to 85
kilodaltons [kDa]) was used as marker for the examined cell
lines (Fig. 2C). The molecular sizes of all detected polypep-
tides could be determined by comparison with a protein
standard (205, 116, 97.4, 66, 45, and 29 kDa; Sigma).
C
*3RLFI
, BMILF1 "
VOL. 63, 1989
I
opd."-
940 NOTES
s_S.| g 2;.7E
. Lr.-=-
s.^': s<..E
aw a
1
.. s ..--. .....
_ te
__ s_^.w.w.
_s ,..
_ ._ _
4_ ;.3_ _*^s t
w _
]WF _
.s_
*..t,la,
_W
ta£
3. a)
0 .. ..
_~~~~~~~-_ _ -
-
_
_ k~ -
.__ hJ
_E 319
A B D I
FIG. 3. Immunoprecipitations of [35S]methionine-labeled cells (A through D) and Western blot showing time course of infection (E). The
preimmune sera (right-hand lanes) and antisera (left-hand lanes) generated against BRLF1 (A), BMLF1 (B), and BZLF1 (C) were incubated
with extracts from TPA-butyrate-induced, in vivo-labeled Raji cells as described in the text. (D) BZLF1-specific immunoprecipitation of Raji
cells superinfected with P3HR-1 virus under cycloheximide inhibition followed by removal of the cycloheximide and labeling of proteins in
the presence of actinomycin D. (E) BZLF1-specific proteins in a time course of infected BJA-B cells (P3HR-1 virus). A total of 106 cells was
harvested at 8 to 24 h postinfection. The lysates were electrophoresed, blotted onto nirocellulose, and analyzed for BZLF1-specific proteins
( ) by antiserum incubation and AP staining. Cross-reaction with a cellular protein is indicated (0).
BMLF1 was expressed as a 60-kDa protein, with addi-
tional smaller and larger uncharacterized species (Fig. 2A).
For BZLF1, a typical double band of 35 and 38 kDa could be
detected in Raji and B95-8 cell extracts. In P3HR-1 cells,
larger BZLF1 proteins (38 and 40 kDa) were expressed,
possibly because of the expression ofWZhet DNA (8, 20, 36)
(Fig. 2B). BRLF1-specific polypeptides could be demon-
strated as double bands with molecular sizes between 94 and
98 kDa depending on the cell line (Fig. 2C). In some
preparations, only the smaller species was detectable by
BRLF1-specific sera.
In extracts from TPA-butyrate-induced Raji cells, poly-
peptides encoded by the ORFs BRLF1, BMLF1, and
BZLF1 could be demonstrated in parallel on one Western
blot by serial incubation of the three specific sera and
staining in different colors (Fig. 2D). In step 1, specific bands
of 35 and 38 kDa were detected by incubation with anti-
BZLF1 serum. When anti-BRLF1 serum was used, proteins
of 96 and 98 kDa were detected. A BMLF1-specific 60-kDa
protein could be shown in step 3.
The protein patterns of the single ORFs in induced Raji
cells were further characterized by immunoprecipitation
after in vivo labeling with [35S]methionine (50 ,uCi/ml for 12
h, 2 days after induction) (Fig. 3). The lysate from 106 cells
was incubated with 10 ,ul of antiserum (preadsorbed with
extract from 107 EBV-negative BJA-B cells). Immune com-
plexes were bound on protein A-Sepharose beads, separated
in polyacrylamide gels, and exposed to autoradiography
films.
Two BRLF1-specific polypeptides of 96 and 98 kDa were
immunoprecipitated in extracts from induced Raji cells (Fig.
3A). The molecular sizes were shown to be virus strain
specific, ranging from 94 to 98 kDa in vivo and from 92 to 96
kDa in vitro (Fig. 4). In vitro translation of BRLF1-specific
RNA from induced Raji cells (hybrid selection) and immu-
noprecipitation with anti-BRLF1 serum identified a 96-kDa
protein (36). Comparison of these results indicates that in
vivo the smaller form represents the precursor of the addi-
tional larger protein in Raji, P3HR-1, and B95-8 cells.
Several proteins heterogeneous in molecular size were
reported to be synthesized from the ORF BMLF1 (6, 24, 28).
We precipitated polypeptides with molecular sizes of be-
tween 45 and 70 kDa in extracts from TPA-butyrate-induced
Raji, P3HR-1, or B95-8 cells. The high sensitivity of the
immunoprecipitation tests (exposure for 3 months in some
cases) enabled us to identify faint BMLF1-specific bands
which could be detected only occasionally in Western blots
(Fig. 2 and 3). RNA data suggest alternative splicing, includ-
ing the short ORF BSLF2 upstream of BMLF1 (6, 12) (Fig.
4). Further posttranslational modifications such as phos-
phorylation and truncated proteins possibly lead to the
heterogeneity in expression. Proteolysis may create addi-
tional fast-migrating species. A characteristic protein of 60
kDa is the predominant BMLF1 product (Fig. 2).
By in vitro translation of BZLF1-specific RNA (Raji and
B95-8), a polypeptide of 38 kDa could be immunoprecipi-
tated (36). In vivo, two proteins of 38 and 35 kDa were
identified (Fig. 2B and D and 3C). Smaller forms of about 30
kDa, which might represent truncated or degraded products
of the 38-kDa precursor, were detectable at times. In EBV-
negative BJA-B cells freshly infected with P3HR-1 virus in
which the initially translated proteins could be examined
with reading frame-specific antisera, the largest polypeptide
(of 40 kDa; P3HR-1 virus specific) was found to be expressed
first. (A total of 106 cells was infected with virus prepared
from 50 ml of P3HR-1 culture. The virus had been pelleted
by centrifugation for 2 h at 20,000 x g from the culture
supernatant after chemical induction for 10 days. Virus
penetration was achieved by incubating the infection assay
for 1 h at room temperature under gentle movement before
the cells were transferred into fresh medium.) The 40-kDa
protein was detectable 10 h postinfection in Western blots,
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FIG. 4. Summary of physical and functional aspects of trans-acting genes of EBV, including BamHI fragments, ORFs, transcripts and
proteins involved in trans-activation, polyadenylation signals (4), promoter sequences ( ), spliced RNAs ( ), and trans-activation
-- - -*). The regulatory properties were derived from references 5, 8, 9, 13-15, 17, 21, 24, 27, 29, 30, 35, 39, and 41 and are described in
detail in the text. Sequence and RNA data were derived from reference 12 and P. J. Farrell (personal communication). The molecular sizes
of the proteins were calculated from the results of separate experiments not shown here. In vitro translation results have been published
elsewhere (36, 37).
whereas at 24 h postinfection, three products of BZLF1
could be identified (Fig. 3E). In Western blot experiments
analyzing different extracts from TPA-butyrate-induced
cells, mainly the 38- and 35-kDa proteins (P3HR-1 cells; 40
and 38 kDa) were detected (Fig. 2B), with additional BZLF1-
specific forms of about 30 kDa in lower amounts.
Low expression of this ORF during conditions favoring
immediate early gene expression could also be shown. For
this, Raji cells were superinfected with P3HR-1 virus for 6 h
under cycloheximide translational block (50 ,ug/ml). The
cycloheximide was then removed, and the cells were labeled
with [35S]methionine in the presence of actinomycin D (2
,ug/ml) for inhibition of transcription for 3 h. A 30-kDa
polypeptide was immunoprecipitated in these extracts by
using BZLF1-specific serum (Fig. 3D). Since larger proteins
were not detected in this test, the role of different BZLF1-
encoded products remains to be clarified. Our results con-
firm recent reports (4; Fuchs, M.S. thesis) that showed
transcription of BZLF1 in Raji cells superinfected with
P3HR-1 virus in the presence of anisomycin and that sug-
gested the immediate early status of this gene.
The expression patterns and known functions of the EBV
trans-activator ORFs BMLF1, BZLF1, and BRLF1 are
summarized in Fig. 4. RNAs and proteins are expressed in a
complex manner. The BMLF1 trans-activator is expressed
from exons of the ORFs BMLF1 and BSLF2 as a 60-kDa
protein with additional modified forms. Sequence analysis
identified BMLF1 homologs in related virus systems (a
52-kDa protein of herpesvirus saimiri, varicella-zoster virus
gene 4, and herpes simplex virus ICP27) (10). BZLF1- and
BRLF1-specific proteins are encoded by one polycistronic
mRNA that is transcribed under anisomycin conditions (4,
35), which distinguish between genes of the early and
immediate early regulatory classes. In this work we demon-
strated the synthesis of a BZLF1-specific 30-kDa immediate
early protein. The BRLF1-encoded proteins were identified
as a doublet which represents a precursor and a modified
higher-molecular-weight form.
The identified trans-activator proteins showed heteroge-
neity in their molecular weights and strain-specific varia-
tions. Each reading frame was found to be expressed in at
least two modifications. To clarify the significance of in vivo
modifications, protein detection in functional assays is re-
quired next. We were ablc to localize BZLF1 and BMLF1
products in the nuclei of B cells, a position presupposed for
DNA interaction. The activities of these EBV trans-acting
proteins were demonstrated to be dependent on the host cell
system (5, 15, 24). Cooperation with cellular, type-specific
factors (1) and their limitation to certain states of cell
differentiation could explain the cell-specific regulation of
EBV trans-activators. The tropism of EBV for B lympho-
cytes on the one hand and epithelial cells on the other has to
be taken into account in future studies of the expression and
activity of trans-acting proteins.
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